,Canonical_Smiles,drug_name,drug_type,Label
0,CC(=O)Nc1ccc(OC(C)C)cc1,O_isopropyl_acetaminophen,1A2-Substrate,negative
1,Cc1ccsc1-c1ccc([C@H](C)C(=O)O)cc1,S_MTPPA,2C9-Substrate,negative
2,CCCC(=O)O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate,negative
3,C/C=C/c1ccccc1,trans_phenylpropene,2E1-Substrate,negative
4,CNNCc1ccc(C(=O)NC(C)C)cc1,Procarbazine,1B1-Substrate,negative
5,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
6,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
7,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
8,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
9,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
10,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
11,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
12,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,2D6-Substrate,negative
13,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
14,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,1A1-Inducer,positive
15,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
16,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,2E1-Substrate,negative
17,COCCCOc1ccnc(CSc2nc3ccccc3[nH]2)c1C,rabeprazole_thioether,2E1-Substrate,negative
18,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
19,CC(=O)C[C@H](c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,Acenocoumarol,-,negative
20,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
21,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
22,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
23,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,Olanzapine,GST-Inducer,negative
24,Nc1ccc(S(N)(=O)=O)cc1,Sulfanilamide,2E1-Inhibitor,negative
25,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
26,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Quercetin,-,negative
27,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
28,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb12,3A4-Substrate,negative
29,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
30,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
31,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
32,Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,Sulfapyridine,-,negative
33,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,Sulfasalazine,-,negative
34,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
35,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,Cytarabine,Multidrug_resistance_protein_1-Inducer,negative
36,CC(C)CCON=O,Amyl Nitrite,GST-Substrate,negative
37,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
38,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,Tecastemizole,-,negative
39,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
40,CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc(S(C)=O)cc1,Sulindac,GST-Inducer,negative
41,CCCCNCc1cc(=O)oc2cc(OC)ccc12,BMAMC,2D6-Substrate,negative
42,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
43,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
44,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,Linezolid,-,negative
45,CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12,Alpidem,-,negative
46,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)NC(N)=O,ABT_438,2E1-Substrate,negative
47,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
48,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,Trazodone,P450_HFLA-Substrate,negative
49,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,Albendazole,1A1-Inducer,positive
50,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,Leflunomide,-,negative
51,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,Vanoxerine,-,negative
52,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
53,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
54,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
55,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
56,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
57,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
58,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,Methyltransferase-Inhibitor,negative
59,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
60,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
61,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
62,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,buprenorphine,2C8-Substrate,negative
63,Cc1cc(Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,Disulfamide,-,negative
64,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,Clofibric acid,-,negative
65,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
66,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,negative
67,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
68,CN(C)C=O,DMF,2E1-Substrate,negative
69,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
70,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2E1-Inhibitor,negative
71,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
72,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
73,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
74,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
75,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
76,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,1A1-Inducer,positive
77,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
78,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,Triamcinolone,SUL-Inducer,negative
79,Oc1ccccc1,Phenol,2E1-Substrate,negative
80,CN[C@H](C)Cc1ccc2c(c1)OCO2,MDMA_R,2D6-Substrate,negative
81,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
82,CC(=O)[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,Progesterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
83,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
84,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,Idarubicin,2D6-Inhibitor,negative
85,CCOc1ccc(NC(C)=O)cc1,Phenacetin,2E1-Substrate,negative
86,COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,Vesnarinone,-,negative
87,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
88,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1,ibuprofen_R,2C9-Substrate,negative
89,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,Tasosartan,-,negative
90,CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1,Gepirone,2D6-Substrate,negative
91,CCN[C@@H](C)Cc1ccccc1,Etilamfetamine,2D6-Substrate,negative
92,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
93,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
94,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,Fesoterodine,2D6-Substrate,negative
95,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Lisuride,2D6-Substrate,negative
96,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Decitabine,Methyltransferase-Inhibitor,negative
97,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
98,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
99,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
100,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
101,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
102,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
103,COc1ccc2c3c1O[C@H]1C(OC(C)=O)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,Thebacon,2D6-Substrate,negative
104,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_S,2C19-Substrate,negative
105,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
106,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Remacemide,-,negative
107,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21,Nalidixic acid,-,negative
108,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,Quinapril,Solute_carrier_family_15_member_2-Inhibitor,negative
109,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
110,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
111,CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,etodolac_R,2C9-Substrate,negative
112,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
113,CC(C)CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_6,3A4-Substrate,negative
114,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Diclofenac,CP2CI-Substrate,negative
115,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,-,negative
116,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
117,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
118,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Testosterone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
119,c1ccccc1,Benzene,-,negative
120,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
121,Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,Ondansetron,2E1-Substrate,negative
122,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,Estrone,4A11-Substrate,negative
123,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
124,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
125,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,budesonide,3A4-Substrate,negative
126,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
127,C[C@@H](Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,Benfluorex,UGT-Inducer,negative
128,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,Montelukast,-,negative
129,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Sufentanil,-,negative
130,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
131,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
132,CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC1,Nateglinide,P450_HFLA-Substrate,negative
133,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
134,O=[N+]([O-])c1cncn1CCN1CCOCC1,Nimorazole,-,negative
135,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Fluphenazine,2E1-Inhibitor,negative
136,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
137,CC(C)COC[C@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Bepridil,2D6-Substrate,negative
138,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
139,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,2C9-Substrate,negative
140,C=CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_13,3A4-Substrate,negative
141,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Alprazolam,P450_HFLA-Substrate,negative
142,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,Ethinylestradiol,P450_HFLA-Substrate,negative
143,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
144,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,Clemastine,2D6-Inhibitor,negative
145,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,ABT_761,2E1-Substrate,negative
146,CC=CC[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,Ciclosporin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
147,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,2E1-Substrate,negative
148,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,Gemfibrozil,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
149,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
150,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
151,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
152,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
153,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
154,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,negative
155,C=CC[C@@H]1C=C(C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](C(C)=C[C@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Tacrolimus,P450_HFLA-Substrate,negative
156,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,eupatilin,2E1-Substrate,negative
157,CN1CCN2c3ncccc3Cc3ccccc3[C@@H]2C1,mirtazapine_R,2D6-Substrate,negative
158,C#CCN(C)[C@H](C)Cc1ccccc1,Selegiline,2E1-Inhibitor,negative
159,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H]1C,Rifapentine,P450_HFLA-Inducer,negative
160,CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O,Tazofelone,-,negative
161,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,Sorafenib,UGT-Inhibitor,negative
162,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
163,Cc1c2ccccc2c(C)c2c1ccc1ccccc12,DMBA,2E1-Substrate,negative
164,COc1cc2c(CCN3CCN(c4cccc(Cl)c4C)CC3)nn(Cc3c[nH]cn3)c2cc1OC,DY_9760e,2D6-Substrate,negative
165,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,warfarin_S,2C19-Substrate,negative
166,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
167,C[C@@H](O)C(=O)O,Milchs√§ure,Monocarboxylate_transporter_1-Substrate,negative
168,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Quinupristin/dalfopristin,3A4-Inhibitor,negative
169,CC(C)NC[C@H](O)COc1cccc2ccccc12,propranolol_S,2D6-Substrate,negative
170,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
171,O=C(Nc1ccc2c(=O)cc(-c3nnn[nH]3)oc2c1)c1ccc(OCCCCc2ccccc2)cc1,Pranlukast,Solute_carrier_family_22_member_11-Inhibitor,negative
172,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
173,O=c1ccc2ccccc2o1,Coumarin,-,negative
174,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,1A1-Inducer,positive
175,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,Irinotecan,P450_HFLA-Substrate,negative
176,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
177,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
178,COc1c2occc2cc2ccc(=O)oc12,Methoxsalen,-,negative
179,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
180,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,Tolbutamide,CP2CI-Substrate,negative
181,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,-,negative
182,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)C=CC=CC[C@@H](C)OC(=O)C[C@H]1O,Spiramycin,3A4-Substrate,negative
183,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,Diltiazem,P450_HFLA-Substrate,negative
184,COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Omeprazole,1A1-Inducer,positive
185,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
186,O[C@@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2,Biperiden,2D6-Inhibitor,negative
187,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
188,CNCCC=C1c2ccccc2CCc2ccccc21,Nortriptyline,2E1-Inhibitor,negative
189,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor,negative
190,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
191,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,Ivermectin,-,negative
192,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
193,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
194,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,Budesonide,SUL-Substrate,negative
195,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
196,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
197,CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1,Salbutamol,-,negative
198,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
199,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3)cc2o1,7_benzyloxy_4_trifluoromethyl_coumarin,2C19-Substrate,negative
200,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
201,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
202,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Losartan,-,negative
203,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
204,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
205,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
206,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,Rupatadine,-,negative
207,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,Morphine,2D6-Substrate,negative
208,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
209,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,1A1-Inducer,positive
210,CN1C(=O)[C@](C)(C2=CCCCC2)C(=O)N=C1O,Hexobarbital,-,negative
211,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,Eletriptan,2D6-Substrate,negative
212,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
213,C=CCN,Trastuzumab,19A-Inhibitor,negative
214,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,Cilostazol,2D6-Substrate,negative
215,CC[C@@H]1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,Tofisopam,3A4-Inhibitor,negative
216,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
217,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,Benzbromarone,-,negative
218,CCCCCOc1ccc2ccc(=O)oc2c1,7_pentoxy_coumarin,3A4-Substrate,negative
219,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
220,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
221,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1A1-Inducer,positive
222,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
223,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
224,O=C(O)CC(O)(CC(=O)O)C(=O)[O-],Sodium Citrate,SUL-Inhibitor,negative
225,CN1CCN(C(=O)NC(Cc2ccccc2)C(=O)NC(C=CS(=O)(=O)c2ccccc2)CCc2ccccc2)CC1,K11777,2E1-Substrate,negative
226,NCC(=O)O,Glycine,GST-Inducer,negative
227,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
228,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,Cefotiam,Solute_carrier_family_22_member_8-Substrate,negative
